 
        
        
        PD98059是一种非 ATP 竞争性的 MEK 抑制剂,对 MEK1 和 MEK2 的 IC50 分别为 2-7 μM 和 50 μM,抑制 MAPK 激活,且对 TCDD 结合具有抑制作用。PD98059阻止小鼠 ES 细胞的分化,增强人类间充质干细胞的脂肪分化,阻止其成骨分化。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | MEK ↓ ↑ | MEK1 ↓ ↑ | MEK1/2 ↓ ↑ | MEK2 ↓ ↑ | MEK5 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Honokiol | ✔ | 98% | |||||||||||||||||
| Mirdametinib | ++++ MEK, IC50: 0.33 nM | 99%+ | |||||||||||||||||
| Binimetinib | +++ MEK, IC50: 12 nM | 99%+ | |||||||||||||||||
| BI-847325 | ++ MEK1, IC50: 25 nM | +++ MEK2, IC50: 4 nM | 99%+ | ||||||||||||||||
| U0126-EtOH | + MEK1, IC50: 0.07 μM | ++ MEK2, IC50: 0.06 μM | 98% | ||||||||||||||||
| GDC-0623 | ++++ MEK1, IC50: 0.13 nM | 99%+ | |||||||||||||||||
| TAK-733 | ++++ MEK1, IC50: 3.2 nM | 99%+ | |||||||||||||||||
| Trametinib | ++++ MEK1, IC50: 0.92 nM | ++++ MEK2, IC50: 1.8 nM | 99%+ | ||||||||||||||||
| Selumetinib | +++ MEK1, Kd: 99 nM MEK1, IC50: 14 nM | + MEK2, Kd: 530 nM | 99%+ | ||||||||||||||||
| CI-1040 | ++ MEK1, IC50: 17 nM | ++ MEK2, IC50: 17 nM | 99%+ | ||||||||||||||||
| Myricetin | ✔ | 98% | |||||||||||||||||
| Refametinib | ++ MEK1, IC50: 19 nM | ++ MEK2, IC50: 47 nM | 99%+ | ||||||||||||||||
| Cobimetinib | +++ MEK1, IC50: 4.2 nM | 99%+ | |||||||||||||||||
| PD98059 | + MEK1, IC50: 2 μM | 99%+ | |||||||||||||||||
| SL327 | + MEK1, IC50: 0.18 μM | + MEK2, IC50: 0.22 μM | AP-1 | 98+% | |||||||||||||||
| PD318088 | ✔ | 99% | |||||||||||||||||
| AZD8330 | +++ MEK1/2, IC50: 7 nM | 99%+ | |||||||||||||||||
| Pimasertib | 98% | ||||||||||||||||||
| (E/Z)-BIX02189 | ++++ MEK5, IC50: 1.5 nM | 99%+ | |||||||||||||||||
| (E/Z)-BIX02188 | +++ MEK5, IC50: 4.3 nM | 99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | MEKs, which are members of the MAPKK family, can activate both ERK1 and ERK2 by catalyzing the phosphorylation on T202/Y204. Also MEK itself can be phosphorylated and activated through Ras when the upstream signaling is activated by extracellular stimuli, including growth factors, hormones etc.. PD98059 is MEK1/2-specific inhibitor with IC50=~10uM (measured by phosphorylation level of MAPK-KA catalyzed by GST-MEK1) with no effect on ERK. Pre-incubation of PD98059 can inhibit PDGF-stimulated tyrosine phosphorylation of MAPK while preventing thymidine incorporation with an IC50 of 7 uM in 3T3 cells. PD98059 did not show significant inhibitory activity on Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, EGF receptor kinase, insulin receptor kinase, PDGFreceptor kinase, and PI3Ks, which shows the high selectivity of it [1]. PD98059 is the first generation small molecule inhibitors of MEK1/2. PD98059 does not interfere with Raf access to MEK1/2 for it did not affect serum-induced MEK1/2 phosphorylation [2]. | 
| 作用机制 | PD 098059 does not complete for ATP binding or MAPK binding to MEK and most likely inhibits through an allosteric mechanism.[1] | 
| Concentration | Treated Time | Description | References | |
| Human intrahepatic biliary epithelial cells (HIBEpiCs) | 10 μM | 24 h | Pretreatment with PD98059 reduced apelin-induced ERK phosphorylation and cholangiocyte proliferation | Hepatology. 2021 Jun;73(6):2411-2428. | 
| Y79 cells | 0.1 µM, 0.2 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM, 12.5 µM | 22 h | To evaluate the effects of PD98059 on the metabolic activity and cytotoxicity of Y79 cells. PD98059 significantly inhibited cellular metabolic activity at a concentration of 3.12 µM or higher, but did not significantly increase cytotoxicity. | Theranostics. 2022 Sep 11;12(15):6705-6722. | 
| huPMCs cells | 0.1 µM, 0.2 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM, 12.5 µM | 22 h | To evaluate the effects of PD98059 on the metabolic activity and cytotoxicity of huPMCs cells. PD98059 did not significantly inhibit cellular metabolic activity at concentrations up to 12.5 µM, nor did it significantly increase cytotoxicity. | Theranostics. 2022 Sep 11;12(15):6705-6722. | 
| MIO-M1 cells | 0.1 µM, 0.2 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM, 12.5 µM | 22 h | To evaluate the effects of PD98059 on the metabolic activity and cytotoxicity of MIO-M1 cells. PD98059 significantly inhibited cellular metabolic activity at a concentration of 1.56 µM or higher, but did not significantly increase cytotoxicity. | Theranostics. 2022 Sep 11;12(15):6705-6722. | 
| U87 cells | 5 μM | 12 h | To investigate the effect of PD98059 on RRM2 overexpression in U87 cells, the results showed that PD98059 inhibited the phosphorylation of ERK1/2 and blocked the upregulation of cyclin B1, cyclin D1, and N-cadherin expression induced by RRM2 overexpression. | Int J Biol Sci. 2019 Jan 1;15(3):533-543. | 
| Human adipose-derived stem cells (hASCs) | 5 μM | 48 h | To investigate the effect of PD98059 on FGF-2-mediated proliferation of hASCs, results showed that PD98059 significantly inhibited FGF-2-mediated cell proliferation. | Stem Cell Res Ther. 2019 Nov 27;10(1):350. | 
| human adipose tissue-derived stem cells (hADSCs) | 40 μM | 30 min | PD98059 abolished the ERK1/2 phosphorylation and proliferation induced by silica NPs | Int J Nanomedicine. 2015 Mar 24;10:2261-72. | 
| MIA-PaCa-2 cells | 25 µM | PD98059 completely blocked KIF15-mediated pancreatic cancer cell proliferation | Br J Cancer. 2017 Jul 11;117(2):245-255. | |
| PANC-1 cells | 25 µM | PD98059 completely blocked KIF15-mediated pancreatic cancer cell proliferation | Br J Cancer. 2017 Jul 11;117(2):245-255. | |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Photo-oxidative damage model | Intravitreal injection | 100 µM | Single injection, lasting 4 days | To evaluate the protective effects of PD98059 on the retina of photo-oxidative damage mice. PD98059 significantly inhibited the phosphorylation of pERK1/2, reduced the expression of the gliotic marker GFAP in Müller cells, and increased the levels of the neuroprotective factor IRBP in photoreceptors. PD98059 also reduced photoreceptor apoptosis in photo-oxidative damage mice and assessed its protective effects on retinal function through OCT and ERG. | Theranostics. 2022 Sep 11;12(15):6705-6722. | 
| Balb/c nude mice | Orthotopic pancreatic cancer transplantation model | Subcutaneous injection | 10 mg/kg | Once daily for 9 weeks | PD98059 blocked KIF15-mediated pancreatic cancer proliferation and prolonged the survival time of mice | Br J Cancer. 2017 Jul 11;117(2):245-255. | 
| Dose | Mice: 10 mg/kg[3] | 
| Administration | i.v. | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 3.74mL 0.75mL 0.37mL | 18.71mL 3.74mL 1.87mL | 37.41mL 7.48mL 3.74mL | |
| CAS号 | 167869-21-8 | 
| 分子式 | C16H13NO3 | 
| 分子量 | 267.28 | 
| SMILES Code | O=C1C=C(C2=CC=CC(OC)=C2N)OC3=C1C=CC=C3 | 
| MDL No. | MFCD00671789 | 
| 别名 | NSC 679828 | 
| 运输 | 蓝冰 | 
| InChI Key | QFWCYNPOPKQOKV-UHFFFAOYSA-N | 
| Pubchem ID | 4713 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C | 
| 溶解方案 | DMSO: 35 mg/mL(130.95 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1